Can learning to manage side effects improve life for neuroendocrine tumor patients?
NCT ID NCT07258810
First seen Dec 16, 2025
Summary
This study looks at whether a therapeutic education program helps patients with neuroendocrine tumors who are taking oral anti-cancer drugs. The researchers will track side effects, treatment adherence, and quality of life in 100 adults over 3 months. The goal is to see if teaching patients how to manage their own care reduces severe side effects and improves their well-being.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE (NE) TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Edouard Herriot University Hospital
Lyon, 69003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral anti-tumor drugs (everolimus, sunitinib, cabozantinib, temozolomide, capecitabine, lenvatinib)
What this could lead to
If successful, this could show that patient education programs help people with neuroendocrine tumors better manage side effects and stick to their oral cancer treatment, potentially improving their quality of life.
What could go wrong
This is a small, early-stage study (100 participants) that only measures outcomes over 3 months. It may not prove that the education program directly causes better outcomes, and results may not apply to all patients or treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.